Cargando…
Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer
BACKGROUND: The EGFR signaling pathway is frequently activated in human ovarian cancer and associated with poor prognosis. However, inhibition of EGFR signaling in patients with recurrent ovarian cancer has been disappointing. It remains to be addressed whether ovarian cancer patients could benefit...
Autores principales: | Wen, Wei, Wu, Jun, Liu, Lucy, Tian, Yan, Buettner, Ralf, Hsieh, Meng-Yin, Horne, David, Dellinger, Thanh H, Han, Ernest S, Jove, Richard, Yim, John H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437681/ https://www.ncbi.nlm.nih.gov/pubmed/25928246 http://dx.doi.org/10.1186/s12943-015-0366-5 |
Ejemplares similares
-
Increasing Antitumor Activity of JAK Inhibitor by Simultaneous Blocking Multiple Survival Signaling Pathways in Human Ovarian Cancer
por: Wen, Wei, et al.
Publicado: (2019) -
Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer
por: Han, Ernest S., et al.
Publicado: (2018) -
Synergistic Anti-Tumor Activity by Targeting Multiple Signaling Pathways in Ovarian Cancer
por: Wen, Wei, et al.
Publicado: (2020) -
Spirooxindole Derivative SOID-8 Induces Apoptosis Associated with Inhibition of JAK2/STAT3 Signaling in Melanoma Cells
por: Tian, Yan, et al.
Publicado: (2012) -
Prognostic Significance of B-Cells and pSTAT3 in Patients with Ovarian Cancer
por: Yang, Chunmei, et al.
Publicado: (2013)